Immuno-Oncology Biomarkers 2010 and Beyond

Symposium on Immuno-Oncology Biomarkers, 2010 and Beyond: Perspectives from the iSBTc Biomarker Task Force

September 30, 2010
Masur Auditorium on the NIH Campus
Building 10, Clinical Center
Bethesda, MD

The primary audience for this meeting included scientists and clinicians from regulatory agencies, industry, and academics who were interested in the development of immune based therapies for the treatment of cancer as well as analysis of the immune impact of other types of clinical interventions.

Topics Included:

Immunologic Monitoring: Standardization and Validation of Assays
Correlation of Immunity to Clinical Response and Potency Assays
Novel Methodologies for Assessing the Immune Landscape: Clinical Utility of Novel Technologies
Recommendations on Incorporation of Biomarkers into the Clinical Arena

Organizers

Lisa H. Butterfield, PhD
University of Pittsburgh

Mary L. (Nora) Disis, MD
University of Washington

Samir N. Khleif, MD
National Cancer Institute (CCR)

Francesco Marincola, MD
National Institutes of Health (CC, DTM)

Collaborating Organizations

Association for Immunotherapy of Cancer (CIMT)
Biotherapy Development Association (BDA)
Cancer Immunotherapy Consortium (CIC)
of the Cancer Research Institute (CRI)
National Institutes of Health, Clinical Center
Nordic Center for Development of Antitumour Vaccines (NCV-Network)

View the iSBTc 2010 Program Supporters.

The Symposium on Immuno-Oncology Biomarkers is a non-accredited continuing medical education event. No credits are offered for physician participation in this educational program.